Marie Sundquist

Dr. Marie Sundquist

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in The Breast
Verified
Journal Article
Closed access
MSMarie Sundquist
Marie Sundquist
LBLars Brudin
Lars Brudin
GTGöran Tejler
Göran Tejler

1 January 2010 in European Journal of Cancer
Verified
Journal Article
Closed access
RBR.W. Blamey
R.W. Blamey
BHB. Hornmark-Stenstam
B. Hornmark-Stenstam
GBGraham Roy Ball
Graham Roy Ball
MBM. Blichert-Toft
M. Blichert-Toft
LCL. Cataliotti
L. Cataliotti
IEIan Ogilvie Ellis
Ian Ogilvie Ellis

1 January 1999 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MSMarie Sundquist
Marie Sundquist
STSten Thorstenson
Sten Thorstenson
LBLars Brudin
Lars Brudin
BNBo Nordenskjöld
Bo Nordenskjöld

31 October 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
NTN. P. Tobin
N. P. Tobin
JHJ. Chuck Harrell
J. Chuck Harrell
JLJ. Lövrot
J. Lövrot
SBS. Egyhazi Brage
S. Egyhazi Brage
CPCharles M Perou
Charles M Perou
LMLena Malmberg
Lena Malmberg
We and others have recently shown that tumor characteristics are altered throughout tumor progression. These findings emphasize the need for re-examination of tumor characteristics at relapse and have led to recommendations from ESMO and the Swedish Breast Cancer group. Here, we aim to determine whether tumor characteristics and molecular subtypes in breast cancer metastases confer clinically relevant prognostic information for patients. The translational aspect of the Swedish multicenter randomized trial called TEX included 111 patients with at least one biopsy from a morphologically confirmed locoregional or distant breast cancer metastasis diagnosed from December 2002 until June 2007. All patients had detailed clinical information, complete follow-up, and metastasis gene expression information (Affymetrix array GPL10379). We assessed the previously published gene expression modules describing biological processes [proliferation, apoptosis, human epidermal receptor 2 (HER2) and estrogen (ER) signaling, tumor invasion, immune response, and angiogenesis] and pathways (Ras, MAPK, PTEN, AKT-MTOR, PI3KCA, IGF1, Src, Myc, E2F3, and β-catenin) and the intrinsic subtypes (PAM50). Furthermore, by contrasting genes expressed in the metastases in relation to survival, we derived a poor metastasis survival signature. A significant reduction in post-relapse breast cancer-specific survival was associated with low-ER receptor signaling and apoptosis gene module scores, and high AKT-MTOR, Ras, and β-catenin module scores. Similarly, intrinsic subtyping of the metastases provided statistically significant post-relapse survival information with the worst survival outcome in the basal-like [hazard ratio (HR) 3.7; 95% confidence interval (CI) 1.3–10.9] and HER2-enriched (HR 4.4; 95% CI 1.5–12.8) subtypes compared with the luminal A subtype. Overall, 25% of the metastases were basal-like, 32% HER2-enriched, 10% luminal A, 28% luminal B, and 5% normal-like. We show that tumor characteristics and molecular subtypes of breast cancer metastases significantly influence post-relapse patient survival, emphasizing that molecular investigations at relapse provide prognostic and clinically relevant information. This is the translational part of the Swedish multicenter and randomized trial TEX, clinicaltrials.gov identifier nct01433614 (http://www.clinicaltrials.gov/ct2/show/nct01433614).

23 September 2011 in Immunogenetics
Verified
Journal Article
Open access
PDF file
LALisa S. Andersson
Lisa S. Andersson
JSJune E. Swinbune
June E. Swinbune
JMJennifer Meadows
Jennifer Meadows
HBHans Broström
Hans Broström
SESusanne Eriksson
Susanne Eriksson
Gabriella LindgrenGabriella Lindgren
Gabriella Lindgren
Insect bite hypersensitivity (IBH) is a chronic allergic dermatitis common in horses. Affected horses mainly react against antigens present in the saliva from the biting midges, Culicoides ssp, and occasionally black flies, Simulium ssp. Because of this insect dependency, the disease is clearly seasonal and prevalence varies between geographical locations. For two distinct horse breeds, we genotyped four microsatellite markers positioned within the MHC class II region and sequenced the highly polymorphic exons two from DRA and DRB3, respectively. Initially, 94 IBH-affected and 93 unaffected Swedish born Icelandic horses were tested for genetic association. These horses had previously been genotyped on the Illumina Equine SNP50 BeadChip, which made it possible to ensure that our study did not suffer from the effects of stratification. The second population consisted of 106 unaffected and 80 IBH-affected Exmoor ponies. We show that variants in the MHC class II region are associated with disease susceptibility (p raw = 2.34 × 10−5), with the same allele (COR112:274) associated in two separate populations. In addition, we combined microsatellite and sequencing data in order to investigate the pattern of homozygosity and show that homozygosity across the entire MHC class II region is associated with a higher risk of developing IBH (p = 0.0013). To our knowledge this is the first time in any atopic dermatitis suffering species, including man, where the same risk allele has been identified in two distinct populations.

1 February 2002 in The Breast
Verified
Journal Article
Closed access
MSMarie Sundquist
Marie Sundquist
STS. Thorstenson
S. Thorstenson
LBL. Brudin
L. Brudin
SWS. Wingren
S. Wingren
BNB. Nordenskjöld
B. Nordenskjöld